Facebook Twitter Instagram
    • Home
    • About Journal
      • Aim and Scope
      • Editorial Board
      • Indexing Info
      • Contact Us
    • Browse Issues
      • Articles in Press
      • Current Issue
      • Past Issues
    • For Authors
      • Instructions to Authors
      • Article Processing Charges
      • Submit your article
      • Downloads
    Facebook Twitter Instagram
    Pharmacognosy Communications
    • Home
    • About Journal
      • Aim and Scope
      • Editorial Board
      • Indexing Info
      • Contact Us
    • Browse Issues
      • Articles in Press
      • Current Issue
      • Past Issues
    • For Authors
      • Instructions to Authors
      • Article Processing Charges
      • Submit your article
      • Downloads
    Pharmacognosy Communications
    retyeyutreu
    Original Article

    The Growth Inhibitory Activity of Tasmannia lanceolata (Poir.) A.C. Sm against the Food-poisoning Pathogen Yersinia enterocolitica

    wadmin1By wadmin1September 1, 2019Updated:August 10, 2021No Comments2 Mins Read
    Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp Email
    Share
    Facebook Twitter LinkedIn WhatsApp Pinterest Email

    Huda Aldosary1, Mitchell Henry Wright2,*, Cameron Jay Lee1, Anthony Carlson Greene1, Ian Edwin Cock1,3,*

    1School of Environment and Science, Griffith University, Brisbane, Queensland, AUSTRALIA.

    2Department of Research and Development, First Choice College, Gold Coast, Queensland, AUSTRALIA.

    3Environmental Futures Research Institute, Griffith University, Brisbane, Queensland, AUSTRALIA

    Pharmacognosy Communications,2019,9,4,143-148.
    DOI:10.5530/pc.2019.4.30
    Published:September 2019
    Type:Original Article

    ABSTRACT:

    Introduction: Yersinia enterocolitica is a major source of food poisoning via the consumption of contaminated meat products, causing acute gastroenteric yersiniosis. Tasmannia lanceolata has been widely documented for its antiseptic properties, repressing the growth of an extensive range of bacteria. Despite this, Tasmannia lanceolata has yet to be been tested for its inhibitory capacity against Y. enterocolitica. Methods: T. lanceolata leaf and berry extracts were prepared by maceration and growth inhibitory activity against a clinical strain of Y. enterocolitica was examined by disc diffusion assays. The MIC values of the extracts were determined to quantify and compare their relative efficacies. Toxicity was determined using an Artemia franciscana nauplii bioassay. Results: T. lanceolata leaf and berry extracts displayed potent growth inhibitory activity in the disc diffusion assay against Y. enterocolitica. The ethyl acetate and chloroform leaf extracts (MICs of 30 and 53 μg/mL respectively) and the hexane berry extract (MIC = 34 μg/mL) were particularly potent growth inhibitors. The methanol and water extracts of both the berry and leaf, as well as the leaf ethyl acetate extract, also had strong growth inhibitory activity against Y. enterocolitica, albeit with a higher MIC values (250-300μg/mL). All other extracts had lower efficacy, although their MIC values also indicated good inhibitory activity (with the exception of the chloroform berry extract). When assessed for toxicity, all T. lanceolata extracts were non-toxic (LC50 values >1000 μg/mL) in the Artemia franciscana bioassay. Conclusion: The non-toxicity of the T. lanceolata berry and leaf extracts, combined with the potent inhibitory bioactivity observed against Y. enterocolitica, demonstrates their potential as therapeutic agents in the prevention and treatment of yersiniosis.

    Keywords:antioxidant, Tasmanian pepper, Tasmannia lanceolata, Yersinia enterocolitica, Yersiniosis, Zoonotic
    Download PDF
    Share. Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp Email
    About Journal
    About Journal

    Pharmacognosy Communications [Phcog Commn.] is a quarterly journal published by Phcog.Net. It is a peer reviewed journal aiming to publish high quality original research articles, methods, techniques and evaluation reports, critical reviews, short communications, commentaries and editorials of all aspects of medicinal plant research. The journal is aimed at a broad readership, publishing articles on all aspects of pharmacognosy, and related fields. The journal aims to increase understanding of pharmacognosy as well as to direct and foster further research through the dissemination of scientific information by the publication of manuscripts. The submission of original contributions in all areas of pharmacognosy are welcome.
    Indexed and Abstracted in : Chemical Abstracts, Excerpta Medica / EMBASE, Google Scholar, CABI Full Text, Ulrich’s International Periodical Directory, ProQuest, Journalseek & Genamics, PhcogBase, EBSCOHost, Academic Search Complete, Open J-Gate, SciACCESS.
    Rapid publication: Average time from submission to first decision is 30 days and from acceptance to In Press online publication is 45 days.
    Open Access Journal: Phcog Commn. is an open access journal, which allows authors to fund their article to be open access from publication.

    © 2025 Pharmacognosy Communications. Maintained by Manuscript TechnoMedia LLP.

    Type above and press Enter to search. Press Esc to cancel.

    Scroll Up